Advertisement

Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose

  • Mats A. Bergman
  • David Granlund
  • Niklas RudholmEmail author
Research Article

Abstract

In 2009 and 2010, the Swedish pharmaceuticals market was reformed. One of the stated policy goals was to achieve low costs for pharmaceutical products dispensed in Sweden. We use price and sales data for off-patent brand-name and generic pharmaceuticals to estimate a log-linear regression model, allowing us to assess how the policy changes affected the cost per defined daily dose. The estimated effect is an 18 % cost reduction per defined daily dose at the retail level and a 34 % reduction in the prices at the wholesale level (pharmacies’ purchase prices). The empirical results suggest that the cost reductions were caused by the introduction of a price cap, an obligation to dispense the lowest-cost generic substitute available in the whole Swedish market, and the introduction of well-defined exchange groups. The reforms thus reduced the cost per defined daily dose for consumers while being advantageous also for the pharmacies, who saw their retail margins increase. However, pharmaceutical firms supplying off-patent pharmaceuticals experienced a clear reduction in the price received for their products.

Keywords

Pharmaceutical industry National pharmacy monopoly  Pharmacy deregulation Competition Generics Pricing 

JEL Classification

D80 D83 L65 I11 

Notes

Acknowledgments

Financial support from the Swedish Competition Authority is gratefully acknowledged. We are also grateful to IMS Sweden and Tillväxtanalys for supplying the data used in this paper. The authors declare that the founding source had no role in the development of the article.

Compliance with ethical standards

Conflicts of Interest

The authors declare that they do not have any conflicts of interest that are relevant to the content of the article.

References

  1. Almarsdottir, A. B., Morgall, J. M., & Björnsdottir, I. (2000). A question of emphasis: Efficiency or equality in the provision of pharmaceuticals. The International Journal of Health Planning and Management, 15(2), 149–161.CrossRefPubMedGoogle Scholar
  2. Almarsdottir, A. B., Morgall, J. M., & Grimsson, A. (2000). Cost containment of pharmaceutical use in Iceland: The impact of liberalization and user charges. Journal of Health Services Research & Policy,. doi: 10.1177/135581960000500209.
  3. Andersson, K., Petzold, M., Sonesson, C., Lonnroth, K., & Carlsten, A. (2006). Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time-series analysis of cost, volume and cost per volume trends in Sweden 1986–2002. Health Policy, 79, 231–243.CrossRefPubMedGoogle Scholar
  4. Anell, A., & Hjelmgren, J. (2002). Implementing competition in the pharmacy sector: Lessons from Iceland and Norway. Applied Health Economics and Health Policy, 1, 149–156.PubMedGoogle Scholar
  5. Anell, A. (2004). Nya villkor för apotek och läkemedelsförsäljning - Erfarenheter från Danmark, Island och Norge (in Swedish). IHE Working Paper 2004:2.Google Scholar
  6. Anis, A. H., Guh, D. P., & Woolcott, J. (2003). Lowering generic drug prices: Less regulation equals more competition. Medical Care, 41, 135–141.CrossRefPubMedGoogle Scholar
  7. Aronsson, T., Bergman, M. A., & Rudholm, N. (2001). The impact of generic drug com-petition on brand name market shares—evidence from micro data. Review of Industrial Organization, 19, 423–433.CrossRefGoogle Scholar
  8. Barros, P. P., & Nunes, L. C. (2010). The impact of pharmaceutical policy measures: An endogenous structural-break approach. Social Science and Medicine, 71, 440–450.CrossRefPubMedGoogle Scholar
  9. Bergman, M. A., & Rudholm, N. (2003). The relative importance of actual and potential competition: Empirical evidence from the pharmaceuticals market. Journal of Industrial Economics, 51, 455–467.CrossRefGoogle Scholar
  10. Brekke, K. R., Grasdal, A. L., & Holmås, T. H. (2009). Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation. European Economic Review, 53, 170–185.CrossRefGoogle Scholar
  11. Brekke, K. R., Holmås, T. H., & Straume, O. R. (2011). Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment. Journal of Public Economics, 95, 624–638.CrossRefGoogle Scholar
  12. Duso, T., Herr, A., & Suppliet, M. (2014). The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics. Health Economics, 23, 1036–1057.CrossRefPubMedGoogle Scholar
  13. Econ. (2004). Evaluering av apotekloven och indexprissystemet (in Norwegian). Report, 2004, 10.Google Scholar
  14. Ganslandt, M., & Maskus, K. (2004). Parallel imports and the pricing of pharmaceutical products: Evidence from the European Union. Journal of Health Economics, 23, 1035–1057.CrossRefPubMedGoogle Scholar
  15. Ghislandi, S., Patrizio, A., & Caludio, J. (2013). The impact of reference pricing in Italy, a decade on. European Journal of Health Economics, 14, 1–11.CrossRefGoogle Scholar
  16. Granlund, D. (2010). Price and welfare effects of a pharmaceutical substitution reform. Journal of Health Economics, 29(6), 856–865.CrossRefPubMedGoogle Scholar
  17. Granlund, D., & Köksal-Ayhan, M.Y. (2014). Parallel Imports and Mandatory Substitution Reform: A Kick or a Muff for Price Competition? The European Journal of Health Economics, in press.Google Scholar
  18. Granlund, D., & Rudholm, N. (2011). Consumer Information and Pharmaceutical Prices: Theory and Evidence. Oxford Bulletin of Economics and Statistics, 73, 230–254.CrossRefGoogle Scholar
  19. Holmberg, C., Kjellberg, H., Axelsson, B. (2003). Läkemedelsdistributionen i Norden - En komparativ studie av aktörer, resurser och aktiviteter (in Swedish). SSE/EFI Working Paper Series in Business Administration No 2003:10.Google Scholar
  20. Kanavos, P., Costa-Font, J., & Seeley, E. (2008). Competition in off-patent drug markets: Issues, regulation and evidence. Economic Policy, 23, 499–544.CrossRefGoogle Scholar
  21. Kaiser, U., Mendez, S. J., Rønde, T., & Ullrich, H. (2014). Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark. Journal of Health Economics, 36, 174–187.CrossRefPubMedGoogle Scholar
  22. Lee, Y.-C., Yan, M.-C., Huang, Y.-T., Liu, C.-H., & Chen, S.-B. (2006). Impacts of cost-containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996–2003. Pharmacoeconomics, 24, 891–902.CrossRefPubMedGoogle Scholar
  23. Mian, A., & Sufi, A. (2012). The effects of fiscal stimulus: Evidence from the 2009 cash for clunkers program. Quarterly Journal of Economics, 127, 1107–1142.CrossRefGoogle Scholar
  24. Ministry of Health and Social Affairs. (2009a). Regeringens proposition 2008/09:145, Omreglering av apoteksmarknaden [The government’s bill 2008/09:145, reregulation of the pharmacy market (in Swedish). http://www.regeringen.se.
  25. Ministry of Health and Social Affairs (2009b). Lag (2009:373) om ändring i lagen (2002:160) om läkemedelsförmåner m.m. [Law (2009:373) about change in law (2002:160) regarding the pharmaceutical benefit scheme etc.] (in Swedish). http://www.riksdagen.se.
  26. Ong, M., Catalano, R., & Hartig, T. (2003). A time-series analysis of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clinical Therapeutics, 25, 1262–1275.CrossRefPubMedGoogle Scholar
  27. Pavcnik, N. (2002). Do pharmaceutical prices respond to potential patient out-of-pocket expenses? RAND Journal of Economics, 33, 469–487.CrossRefGoogle Scholar
  28. Puig-Junoy, J. (2007). The impact of generic reference pricing interventions in the statin market. Health Policy, 84, 14–29.CrossRefPubMedGoogle Scholar
  29. Puig-Junoy, J. (2010). Impact of European pharmaceutical price regulation on generic price competition: A review. Pharmacoeconomics, 28, 649–663.CrossRefPubMedGoogle Scholar
  30. Statskontoret. (2013). En omreglerad apoteksmarknad (in Swedish). Final report, 2013, 7.Google Scholar
  31. Tillväxtanalys. (2014). Apoteksmarknadensomreglering - Effekter på följsamhet, priser och kostnader per dagsdos (in Swedish). Working Paper 2012:19.Google Scholar
  32. Vårdanalys. (2014). Låt den rätte komma in (in Swedish). Report, 2014, 3.Google Scholar
  33. Yfantopoulos, J. (2008). Pharmaceutical pricing and reimbursement reforms in Greece. European Journal of Health Economics, 9, 87–97.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Mats A. Bergman
    • 1
    • 2
  • David Granlund
    • 3
  • Niklas Rudholm
    • 2
    • 4
    Email author
  1. 1.Södertörn UniversityHuddingeSweden
  2. 2.HUI ResearchStockholmSweden
  3. 3.Department of EconomicsUmeå UniversityUmeåSweden
  4. 4.The School of Technology and Business StudiesDalarna UniversityFalunSweden

Personalised recommendations